Few real-world studies have investigated the risks of hematuria and proteinuria associated with rosuvastatin use. Rosuvastatin may increase the risk of hematuria, proteinuria, and kidney failure, ...

Compared with atorvastatin, rosuvastatin was associated with an 8% higher risk of hematuria (blood in the urine), a 17% higher risk of proteinuria (protein in the urine), and a 15% higher risk of ...

Rosuvastatin is a lipophilic statin containing a fluorinated phenyl group and a polar methane sulfonamide group, which provide multiple sites contributing to a stronger interaction with ...

Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...

A head-to-head comparison of two popular lipid-lowering medications suggests that rosuvastatin may be a better option than atorvastatin when it comes to decreasing the risk of all-cause mortality and ...

November 9, 2007 (Wilmington, Delaware) – The US FDA has granted an additional indication for rosuvastatin (Crestor, AstraZeneca), as an adjunct to diet to slow the progression of atherosclerosis in ...